How Investors Are Reacting To Arcus Biosciences (RCUS) Nature‑Published ARC‑20 Kidney Cancer Biomarker Data
Arcus Biosciences' Nature-published ARC-20 study data shows that casdatifan monotherapy for metastatic clear cell renal cell carcinoma links deeper HIF‑2α inhibition to changes in the biomarker serum EPO, with greater EPO suppression associated with higher response rates and longer progression‑free survival. This strengthens the biological rationale for casdatifan, potentially expanding its role in kidney cancer treatment as seen in the collaboration with Bristol Myers Squibb for the ROSETTA RCC‑208 trial. While some analysts project significant revenue and earnings growth for Arcus Biosciences, others remain more cautious, highlighting varying perspectives on the company's future investment narrative and fair value.
If You Invested $1,000 in Arcus Bioscience (RCUS)
This article analyzes the historical performance of investing $1,000 in Arcus Bioscience (RCUS) over various periods, showing significant returns in the last year but more modest or negative returns over longer durations. It details Arcus Bioscience's focus on developing cancer and inflammatory disease treatments, its pipeline including casdatifan, quemliclustat, domvanalimab, and zimberelimab, and its strategic collaborations with Gilead Sciences and Taiho Pharmaceutical. The company's financial approach, risk profile as a clinical-stage biopharmaceutical company, and revenue model based on collaborations rather than product sales are also discussed.
How Investors Are Reacting To Arcus Biosciences (RCUS) Nature‑Published ARC‑20 Kidney Cancer Biomarker Data
Arcus Biosciences' recently published ARC-20 study data in Nature shows a link between deeper HIF‑2α inhibition and changes in serum EPO, indicating a higher response rate and longer progression-free survival for casdatifan monotherapy in kidney cancer. This strengthens the biological rationale for casdatifan and impacts Arcus Biosciences' investment narrative, although regulatory and execution risks for its clinical pipeline remain. The company's future treatment settings and financial forecasts are closely tied to successful clinical readouts and external collaborations.
RCUS - Arcus Biosciences Inc Latest SEC Filings
This article provides a snapshot of Arcus Biosciences Inc (RCUS) with its latest financial data, key performance indicators, and market statistics as of July 1, 2026. It covers various metrics including market capitalization, income, sales, insider and institutional ownership, profitability ratios, and stock performance over different periods. The data indicates recent stock price changes, volume, volatility, and analyst recommendations.
HIF-2a inhibition with casdatifan (IMAGE)
New research published in Nature details the inhibition of HIF-2α with casdatifan in advanced kidney cancer patients. The image provided illustrates how casdatifan binds within the HIF-2α PAS-B pocket, disrupting hypoxia signaling in the renal cell carcinoma microenvironment. This study, conducted by Arcus Biosciences Inc, links clinical activity with HIF-2α biology.
New research published in Nature links clinical activity with HIF‑2a biology in advanced kidney cancer patients treated with casdatifan
New research published in Nature details findings from the ARC-20 study, highlighting the clinical activity of casdatifan, a HIF-2a inhibitor, in advanced kidney cancer patients. The study demonstrates a correlation between deep suppression of serum EPO and improved clinical outcomes, including higher response rates and longer progression-free survival. These results support casdatifan as a potential best-in-class HIF-2a inhibitor and validate EPO as a key biomarker for HIF-2a inhibition in clear cell renal cell carcinoma.
Nature study links a kidney-cancer biomarker to casdatifan benefit
Arcus Biosciences announced new research published in Nature, linking clinical outcomes of patients treated with the HIF-2a inhibitor casdatifan to changes in the biomarker erythropoietin (EPO). The study, ARC-20, showed that deeper suppression of serum EPO correlated with higher response rates and longer progression-free survival in advanced kidney cancer patients. Casdatifan monotherapy demonstrated a median progression-free survival of 12.2 months in pre-treated patients, with an acceptable safety profile, validating EPO as a key biomarker for HIF-2a inhibition.
ETFs Investing in Arcus Biosciences, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold shares of Arcus Biosciences, Inc. (RCUS). It provides a detailed table including each ETF's market value, weight of RCUS stock in the fund, issuer, management style, focus, expense ratio, assets under management (AUM), price, change, relative volume, and 3-year NAV total return. The ETFs cover a range of investment strategies, primarily focusing on small-cap, health care, and biotechnology sectors.
Arcus Biosciences, Inc. Actuals & Estimates (NYSE:RCUS)
This article provides an overview of Arcus Biosciences, Inc. (RCUS) stock performance, analyst estimates, and financial data. It details recent stock price movements, historical highs and lows, market capitalization, and upcoming earnings dates. The company's financial actuals and estimates for income, balance sheet, and cash flow are highlighted, along with Q&A about the stock.
RCUS Forecast — Price Target — Prediction for 2027
The article provides a forecast for Arcus Biosciences, Inc. (RCUS) stock, including analyst price targets and future predictions. It details the stock's current price, historical performance, earnings reports, revenue, market capitalization, and volatility, along with answers to frequently asked questions about the company's financials and stock performance.
Form 4 Arcus Biosciences Inc For: 24 June By Investing.com
This article reports on a Form 4 filing for Arcus Biosciences Inc. on June 24, as published by Investing.com. It indicates that the company's stock symbol is RCUS and that its price has increased by 2.48%. The content is essentially a brief announcement of the filing without further details about its contents.
Arcus awards two new employees stock options, RSUs
Arcus Biosciences, a clinical-stage biopharmaceutical company, announced it has granted stock options and restricted stock units to two new employees. These inducement awards, totaling 18,400 options and 9,250 RSUs, were issued under the company's 2020 Inducement Plan, consistent with NYSE rules. The awards aim to attract and retain talent for the company's focus on developing treatments for cancer and inflammatory diseases.
Arcus Biosciences president sells $877,501 in company stock
Juan C. Jaen, President of Arcus Biosciences, Inc. (NASDAQ:RCUS), sold 31,431 shares of company stock for approximately $877,501 through a Rule 10b5-1 trading plan. The sales occurred between June 22 and June 24, 2026, with prices ranging from $27.0313 to $29.6595 per share. These transactions took place while the stock was near its InvestingPro 52-week high, and the company is deemed overvalued by InvestingPro analysis despite recent positive analyst coverage from Truist Securities.
Trust sells 25,000+ RCUS Class A shares (RCUS) in two Rule 144 transactions
A trust has sold over 25,000 Class A shares of Arcus Biosciences (RCUS) in two separate Rule 144 transactions totaling over $686,000. These sales, occurring on June 22 and June 23, 2026, were reported under Rule 144 for secondary sales by an affiliated trust named The Juan Carlos Jaen and Anita Galeana 2000 Trust. The shares were originally acquired as Restricted Stock Units (RSUs) and the company's outstanding shares are 125,773,162 as of June 24, 2026.
Arcus Biosciences (RCUS) president sells 31K shares under 10b5-1 plan
Arcus Biosciences president Juan C. Jaen, through a trust, sold 31,431 shares of common stock between June 22-24, 2026, under a pre-arranged Rule 10b5-1 trading plan. The shares were sold at weighted average prices ranging from $27.03 to $29.66. Following these transactions, Jaen's trust still indirectly holds 890,809 shares, and he directly holds 378,291 shares, including unvested RSUs and shares acquired through the Employee Stock Purchase Plan.
Arcus Biosciences stock hits 52-week high at $28.79 By Investing.com
Arcus Biosciences (RCUS) stock reached a new 52-week high of $28.79, marking a 226.91% increase over the past year, reflecting strong investor confidence despite recent financial results falling short of expectations. According to InvestingPro, the stock is currently trading above its Fair Value, placing it on the "Most Overvalued" list. Truist Securities has initiated coverage with a buy rating and a price target of $35 due to the potential of casdatifan in renal cell carcinoma.
Arcus Biosciences Jumps 5.1% Amid Sector-Wide Rally
Arcus Biosciences (RCUS) saw its shares jump 5.1% on Monday, closing at $25.55, as part of a broad sector-wide rally that also benefited other biotechnology companies like VKTX, IDYA, and RLAY. The surge, which occurred on a volume of 219,198 shares, was attributed to widespread buying interest and renewed investor optimism in the biotechnology sector rather than any company-specific news. Investors are advised to monitor whether this sector momentum will be sustained.
Form 144 Arcus Biosciences For: 22 June By Investing.com
This article reports on the filing of Form 144 for Arcus Biosciences for June 22. It lists RCUS with a 12.01% increase. The content is brief and primarily focuses on this specific financial filing.
RCUS (NYSE) plans sale of 25,000 Class A shares on 06/22/2026
Arcus Biosciences, Inc. (RCUS) has filed a Form 144 to report a proposed sale of 25,000 Class A common shares on the NYSE, with an execution date set for June 22, 2026. The shares were acquired as compensation in the form of Restricted Stock Units (RSUs) with various grant dates. This filing indicates a planned transaction but does not specify the selling holder's identity or cash-flow treatment.
Arcus Biosciences Jumps 5.1% Amid Sector-Wide Rally
Arcus Biosciences (RCUS) saw its shares surge by 5.1% on Monday, closing at $25.55, driven by a broad sector-wide rally in biotechnology stocks. The increase was not attributed to company-specific news but rather to a collective upward trend among its peers, with other companies like VKTX, IDYA, and RLAY also experiencing gains. This suggests a renewed investor interest in the biotechnology sector as a whole.
Arcus Biosciences Inc (RCUS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Arcus Biosciences Inc (RCUS), listing major shareholders and their proportions, as well as categorizing shareholder types by proportion. It also provides a historical overview of institutional shareholding data from Q4 2023 to Q1 2026, showing changes in the number of institutions and shares held. Additionally, the article highlights significant shareholder activity and lists related ETFs that hold RCUS shares.
Arcus Biosciences Inc (RCUS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Arcus Biosciences Inc (RCUS), detailing its business segments. As of April 6, the company's revenue primarily comes from license and development services (89.47%), with collaboration revenue making up the remaining 10.53%. The report includes financial figures for various fiscal years and quarters, though some regional data has not yet been disclosed.
Arcus Biosciences (RCUS) director receives 5,700 RSUs and 16,900 stock options
Arcus Biosciences director Nicole Lambert was granted 5,700 restricted stock units and options to purchase 16,900 shares of common stock at an exercise price of $23.30. These equity awards, received on June 11, 2026, will vest fully on the earlier of June 11, 2027, or the next annual stockholders' meeting, or immediately upon a change in control of the company. Following these grants, Lambert directly holds 43,000 shares of Arcus Biosciences Common Stock.
Arcus Biosciences Stockholders Back Directors and Governance Measures
Arcus Biosciences stockholders re-elected four Class II directors, including Dietmar Berger, David Lacey, Nicole Lambert, and Johanna Mercier, to serve until the 2029 annual meeting, demonstrating continued confidence in the company's leadership. Shareholders also ratified Ernst & Young LLP as the independent accounting firm and approved executive compensation, solidifying stability in Arcus Biosciences' governance. While TipRanks' AI Analyst "Spark" rates RCUS as Neutral due to weak financial performance, it notes a strong cash runway and upcoming clinical catalysts.
Director David L. Lacey receives RCUS stock awards at Arcus Biosciences (RCUS)
David L. Lacey, a director at Arcus Biosciences (RCUS), received 5,700 restricted stock units (RSUs) and a stock option for 16,900 shares with an exercise price of $23.30. These awards vest on the earlier of June 11, 2027, or the next annual stockholders' meeting, and will fully vest upon a change in control. Following these grants, his direct common stock holdings total 76,652 shares.
Arcus Biosciences (RCUS) grants director RSUs and stock options
Arcus Biosciences director Patrick Machado was granted new equity awards on June 11, 2026. These awards include 5,700 restricted stock units (RSUs) and stock options for 16,900 shares at an exercise price of $23.30, both vesting by June 11, 2027, or the next annual stockholders' meeting. Following these grants, Machado directly holds 44,300 shares of common stock in Arcus Biosciences, with these transactions classified as compensation rather than open-market purchases.
Arcus Biosciences counsel exercises 34,090 options | RCUS Insider Trading
Arcus Biosciences General Counsel Carolyn C. Tang exercised 34,090 stock options at $2.574 per share on June 11, 2026. This derivative exercise completely vested the options and leaves Tang with 184,607 common shares, which also include shares from the company's Employee Stock Purchase Plan and unvested RSU awards. The transaction is categorized as a moderate impact with a neutral sentiment, reflecting a conversion of existing rights rather than an open-market purchase.
[Form 4] Arcus Biosciences, Inc. Insider Trading Activity
Arcus Biosciences director Kathryn E. Falberg reported new equity awards, including 5,700 restricted stock units and stock options for 16,900 shares at an exercise price of $23.30. These awards vest on June 11, 2027, or the next annual meeting, with acceleration upon a change in control. Following these transactions, Falberg directly holds 44,300 shares and indirectly 132,106 shares through a trust.
Arcus Biosciences (NYSE: RCUS) reports 2026 shareholder vote results
Arcus Biosciences (NYSE: RCUS) announced the results of its annual meeting held on June 11, 2026, where all management proposals were approved. Shareholders elected four Class II directors to serve until 2029, ratified Ernst & Young LLP as the independent auditor for fiscal year 2026, and approved the compensation of named executive officers on an advisory basis. The report details the specific vote counts for each proposal, including votes for, votes against, abstentions, and broker non-votes.
Arcus Biosciences Jumps 6.9% Amid Sector-Wide Rally
Arcus Biosciences, Inc. (RCUS) shares surged 6.9% to $23.64 on Thursday, driven by a broad rally across the biotechnology sector. The increase was attributed to coordinated buying among biotech peers, indicating renewed investor interest in growth-oriented healthcare equities rather than company-specific news. Investors are advised to monitor the sector's sustained momentum and potential company-specific catalysts for Arcus.
Is Arcus Biosciences (RCUS) Using the ROSETTA Trial Tie-Up to Quietly Reframe Its RCC Strategy?
Arcus Biosciences is collaborating with Bristol Myers Squibb on a clinical trial (ROSETTA RCC-208) involving Arcus's HIF-2a inhibitor, casdatifan, for renal cell carcinoma. This non-exclusive deal means any positive data from casdatifan's inclusion in new combination arms will benefit Arcus's economics, potentially influencing investor perspective on its upcoming 2026 RCC readouts and long-term revenue. While this collaboration broadens casdatifan's testing, the primary catalyst for Arcus remains the pivotal 'go or no go' decisions for RCC in 2026.
Arcus Biosciences Drops 7.0% After LifeSci Capital Initiates at Outperform
Arcus Biosciences (RCUS) shares fell 7.0% despite LifeSci Capital initiating coverage with an "Outperform" rating and a $46 price target, significantly higher than its current trading price of $22.00. This disconnect highlights the volatile nature of biotech stocks, where clinical developments and regulatory news often outweigh analyst optimism. Investors may be de-risking positions or reacting to broader sector weakness, suggesting caution despite the potential long-term upside identified by the analyst.
Arcus Biosciences Inc at Goldman Sachs Healthcare Conference Transcript
This article provides the transcript from the Arcus Biosciences Inc. (NYSE:RCUS) presentation at the Goldman Sachs Healthcare Conference. Terry Rosen, Chairman, CEO, and Co-Founder, introduced the company's focus on strong R&D, particularly in small molecules where existing validation exists but better molecules are needed. He highlighted "Casdatafan" as their most valuable program.
What Did Arcus Biosciences Highlight at the Goldman Sachs Healthcare Conference
Arcus Biosciences presented at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting its lead oncology asset, casdatifan, for renal cell carcinoma, which it projects as a $5-10 billion commercial opportunity. The company emphasized its robust financial position, with cash reserves extending into late 2028, and a diverse pipeline beyond casdatifan, including immunology candidates. Despite a Q1 2026 net loss, analysts maintain a "Buy" consensus with a median price target of $34.50, reflecting confidence in its strategic partnerships and clinical development.
New hire at Arcus Biosciences gets stock options and RSUs
Arcus Biosciences, a clinical-stage biopharmaceutical company, announced that its Compensation Committee granted a new employee inducement equity awards. These awards include options to purchase 2,850 shares of common stock at an exercise price of $23.32 and restricted stock units to acquire 1,450 shares. This grant was made under the company's 2020 Inducement Plan, in line with the "inducement exception" of NYSE Listed Company Manual Rule 303A.08.
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Arcus Biosciences, Inc. (NYSE:RCUS) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $35.10, despite mixed recent updates. The company continues to report significant losses, missing EPS and revenue expectations, and is projected to remain unprofitable for the current fiscal year. Insider selling has also been noted, further complicating the company's financial outlook.
LifeSci Capital Maintains Arcus Biosciences(RCUS.US) With Buy Rating, Maintains Target Price $46
LifeSci Capital has reiterated its Buy rating for Arcus Biosciences (RCUS.US), maintaining a target price of $46. This reflects a continued positive outlook on the company's stock performance.
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $36.73, Implies 58% Upside
Arcus Biosciences, Inc.'s average 12-month price target has been increased to $36.73 from $35.75, representing a potential upside of approximately 58% based on the Jun. 5 closing price. This revised target comes from estimates by 11 analysts, with individual forecasts ranging from $22 to $47 per share. The consensus rating for RCUS remains a "Buy" among 12 analysts, including 10 Buys and 2 Holds.
A Look At Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness
Arcus Biosciences (RCUS) has experienced recent stock price weakness, but a narrative valuation suggests it is 33.4% undervalued at $23.19 compared to a fair value of $34.82, largely due to its promising kidney cancer drug, casdatifan. However, its current Price/Sales ratio of 12.4x is higher than the US Biotechs industry average, signaling caution despite its potential for future growth. Investors are encouraged to consider both the growth potential and the sales multiple in their assessment.
A Look At Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness
Arcus Biosciences (RCUS) has experienced recent stock price weakness, declining 6.1% on the day and 10.8% over the past month, but still showing a 132.6% one-year return. Despite being a clinical-stage company with significant losses, its valuation suggests it might be undervalued, particularly due to its developing kidney cancer franchise and HIF-2 alpha inhibitor. While a narrative fair value suggests it's 33.4% undervalued, its price-to-sales ratio is higher than the industry average, signaling some caution.
Is Arcus‑BMS Kidney Cancer Collaboration Altering The Investment Case For Arcus Biosciences (RCUS)?
Arcus Biosciences and Bristol Myers Squibb have formed a clinical trial collaboration to evaluate Arcus's HIF-2α inhibitor casdatifan with BMS’s bispecific T‑cell engager pumitamig for advanced renal cell carcinoma. This collaboration, which expands casdatifan's role in kidney cancer trials, could strengthen Arcus's investment narrative, especially after a recent trial discontinuation narrowed its focus. While providing validation, the partnership doesn't immediately mitigate regulatory and clinical risks associated with Arcus's key programs.
RCUS Initiated Coverage by LifeSci Capital -- Rating Set to Outp
LifeSci Capital has initiated coverage on Arcus Biosciences (RCUS) with an Outperform rating and a price target of $46.00, signaling a positive outlook for the biopharmaceutical company. However, GuruFocus indicates that RCUS is significantly overvalued at its current price of $25.03, with a GF Value™ of $14.77, and has a GF Score™ of 52/100 due to weak profitability despite some financial strength. Insider activity also shows more sales than buys recently, suggesting caution for potential investors.
Arcus Biosciences Jumps 5.7% Amid Sector-Wide Rally
Arcus Biosciences (RCUS) saw its shares jump 5.7% to $25.23 on Thursday, participating in a broad sector-wide rally that benefited several biotechnology companies. This increase, which saw other peers gain between 3.8% and 11.1%, signals a renewed investor interest in biotech stocks. The coordinated performance across the sector suggests a shift in broader market sentiment rather than company-specific news, extending Arcus Biosciences' market capitalization to $3.2 billion.
Is Arcus‑BMS Kidney Cancer Collaboration Altering The Investment Case For Arcus Biosciences (RCUS)?
Arcus Biosciences recently announced a collaboration with Bristol Myers Squibb (BMS) to evaluate its HIF-2α inhibitor, casdatifan, in combination with BMS’s pumitamig in a Phase 1/2 kidney cancer study. While this expands Arcus's clinical presence in renal cell carcinoma, particularly in TKI-free treatments, it does not fundamentally alter the near-term regulatory and clinical risks associated with their pipeline. The collaboration is seen as a validation point for Arcus's kidney cancer strategy, especially after the discontinuation of their STAR-121 lung cancer trial, which increased focus and funding risks on their narrower portfolio.
Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment
Arcus Biosciences has expanded its collaboration with Bristol Myers Squibb to include the joint development and commercialization of a novel kidney cancer treatment. This partnership brings together specialized expertise to advance new therapeutic options for patients with renal cell carcinoma. The agreement aims to accelerate the drug's journey through clinical trials and ultimately to market.
Arcus to Supply Experimental Kidney Cancer Drug for Myers Squibb Trial
Arcus Biosciences will supply its experimental cancer drug, casdatifan, for Bristol Myers Squibb's ROSETTA RCC-208 phase 1/2 clinical trial in advanced kidney cancer. The drug will be tested in combination with Bristol Myers Squibb's experimental pumitamig, a two-in-one therapy also developed with BioNTech. Both companies retain full rights to their respective drugs, aiming to develop new, more effective treatment approaches for kidney tumors, a disease with limited options.
New drug combo from Arcus and BMS targets advanced kidney cancer
Arcus Biosciences and Bristol Myers Squibb have announced a clinical trial collaboration to evaluate Arcus's investigational HIF-2a inhibitor, casdatifan, in combination with BMS's PD-L1/VEGF-A bispecific antibody, pumitamig, for advanced renal cell carcinoma. This partnership aims to develop a novel treatment regimen that provides sustained tumor control, particularly offering TKI-free options for patients. Both companies will retain rights to their respective assets, emphasizing the potential for casdatifan as a backbone therapy in kidney cancer treatment.
Arcus Biosciences Drops 6.0% Amid Sector-Wide Selling
Arcus Biosciences stock fell 6.0% to $24.14 on Tuesday due to a broad sell-off affecting biotechnology stocks, rather than company-specific news. Several peer companies experienced similar declines, suggesting a sector-wide retreat from risk assets or profit-taking by investors. The stock's performance indicates that investors are exercising caution toward biotechnology names in the near term.
Arcus Biosciences chief accounting officer sells $66,023 in stock
Alexander Azoy, Chief Accounting Officer at Arcus Biosciences, sold 2,562 shares of the company’s common stock for $66,023 on June 1, 2026. This sale, conducted under a 10b5-1 plan, follows a significant 187% surge in RCUS stock over the past year. Despite the stock's performance, the company recently missed Q1 2026 earnings and revenue estimates, though Truist Securities initiated a "buy" rating with a raised price target due to potential in casdatifan.
Arcus Biosciences (RCUS) CAO 10b5-1 sale of 2,562 shares
Arcus Biosciences' Chief Accounting Officer, Alexander Azoy, sold 2,562 shares of common stock at a weighted average price of $25.7704 per share through a pre-arranged Rule 10b5-1 trading plan. These shares were originally acquired via the company's Employee Stock Purchase Plan. Following this transaction, Azoy directly holds 39,581 shares, including unvested restricted stock units.
